Surge in spousal murders in India reflects deeper societal issues: NMHP Advisor
The recent tragic murder of Raja Raghuvanshi, a young businessman from Indore, allegedly killed by his wife, Sonam Raghuvanshi, during their honeymoon in Meghalaya is a heartbreaking reminder of the devastation caused by dishonesty in relationships.
Marriage is a sacred bond built on trust and mutual respect. When these values are absent, the consequences can be catastrophic, said Dr Naresh, noted Mental Health Expert.
Talking to UNI after addressing a Continuing Medical Education Programme (CME) on "Understanding Toxic Relationships" organised by the Hyderabad-based Institute of Mental Health here on Wednesday, Dr Purohit emphasised that instead of resorting to violence, individuals must have the courage to choose divorce or to walk away from marriages that conflict with their true feelings. Taking an innocent life is never the answer, it creates a cycle of pain and suffering for all involved.
Quoting his recent research paper titled "The Psychology Behind Spousal Killings", the Principal Investigator for the Association of Studies In Mental Care, pointed that one of the leading factors that makes spouses commit such heinous act is the desire to take over, control and dominate the relationship; and the failure to achieve that can lead to frustration, prompting them to kill their partner.
"The relationships where the partner has the intense ambition of jealousy and possessiveness can fuel anger and resentment, whereas little events can take up huge manifestations like killing or murdering the partner," he added
"The past experiences of an individual can lead to such killings. Where prior bad experiences may erode trust in the institution of marriage, leading to the killing of the partner," he said
He averred that several personality disorders, such as narcissistic personality disorder, where one is extremely egotistical or is very suspicious of the other partner, can predispose individuals to aggressive behaviors and a lack of empathy.
"According to the National Crime Records Bureau (NCRB) homicides resulting from love affairs and marital relationships are the third and fourth most prevalent motives for murder in India. Statistically, approximately one in ten murders in the nation is perpetrated by a lover, spouse, or partner."
"From 2010 to 2014, the proportion of murders linked to love affairs and relationships fluctuated between 7 percent and 8 percent. In contrast, from 2015 to 2022, this percentage increased to between 10 percent and 11 per cent, and the trend shows no signs of abating," the renowned physician added.
Experts pointed out that in most spousal crimes, the person isn't mentally ill; they just don't care how their emotions and actions affect others. It's much more than just poor mental well-being, it's complete moral erosion.
UNI KNR RN
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Counselling for med seat admissions on Aug 1
Panaji: 'Counselling will be held for medicine, dentistry, nursing, and allied health programmes. For ayurveda and homeopathy seats, the counselling schedule will be declared when the respective council declares their admission schedules,' said an official. There are around 170 state quota MBBS seats in Goa. 'The eligibility list will be declared by July 24 and the merit list by July 30 for NEET-based programmes. Admissions for pharmacy seats too will be held along with the medicine seat admissions as the NEET scores have come now. Pharmacy seat admissions are done either on the NEET score or the JEE Main score — whichever is higher — in physics and chemistry,' the official said. The first round of engineering seat admissions was completed, and the second round is expected to be held in Aug. Around 450 of 1,700 seats went vacant after the first admission round. 'Vacancies have been observed after the economically backward sections (EWS) quota was introduced. Before the quota, there were around 1,200 engineering seats in the state, of which around 1,100 would be filled. After the quota seats were added, a similar number of seats have been getting filled, but the additional ones are going vacant,' said an official. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like An engineer reveals: One simple trick to get internet without a subscription Techno Mag Learn More Undo As has been the trend in recent years, the directorate has proposed to state govt to relax the JEE criteria in the subsequent engineering admission rounds to allow the vacant seats to be filled. 'Even after relaxing the criteria, just around 50 more seats are seen to be getting filled in subsequent rounds. Relaxing JEE criteria allows any student with 45% marks in physics, chemistry, and maths in Class XII to apply for an engineering seat, even if he or she has not appeared for the JEE for some reason,' said the official. Most of the vacant seats are at the state's private engineering colleges, while those at the govt-run Goa Engineering College have mostly been taken.
The Hindu
an hour ago
- The Hindu
Special DigiLocker technology for nurses' registration
For what is touted to be the first time in the country, a special DigiLocker-based technology developed by the Karnataka State Nursing Council for the registration of nurses is being implemented. In a press release, Sharanaprakash Patil, Minister for medical education, said that the new technology, which facilitates the issuance of registration certificates through Aadhaar-based DigiLocker e-KYC, will be officially launched on Tuesday, July 15 by Chief Minister Siddaramaiah. The system has been developed in collaboration with UIDAI, C-eG, Rajiv Gandhi University of Health Sciences (RGUHS) and the Karnataka State Nursing Examination Board, the minister stated. With this technology, the Karnataka State Nursing Council can directly retrieve personal data, address, photo, and other details of nurses from the Aadhaar server through e-KYC. Previously, nursing candidates from various districts had to travel to the Council's central office in Bengaluru for registration, minister explained. New technology to avoid hassles Nurses from within and outside the State were forced to spend thousands of rupees on food and accommodation solely for registration purposes. They also had to wait in long queues at the Bengaluru office. Many women, pregnant women and new mothers faced considerable inconvenience. Dr. Patil said that the implementation of this new technology puts an end to all these issues. Helps prevent forgery The new DigiLocker-Requester technology enables the Karnataka Nursing Council to directly fetch Aadhaar cards, SSLC and PUC marks cards, and other certificates from respective examination boards. Using technology adopted by RGUHS and the Karnataka State Nursing Examination Board, examination results will be directly accessed by the Nursing Council. Later, through DigiLocker-Issuer, registration certificates will be issued directly to nurses.
Mint
an hour ago
- Mint
Sacrifices, trade-offs behind big win, says Glenmark's Saldanha
The road to drug discovery is long, arduous and littered with failure, but the payoff at the end makes it worth the trouble. It's a lesson that India's best pharmaceutical entrepreneurs knew all along. Yet, it took a Glenn Saldanha to prove it. 'We were always resilient in how we approached innovation. I think that's what finally rewarded us," Saldanha, chief executive officer and managing director of Glenmark Pharmaceuticals Ltd, told Mint in an exclusive interview. He was referring to one of the largest deals for an Indian biopharma firm after Glenmark's US-based unit Ichnos Glenmark Innovation (IGI) secured a $700-million exclusive licensing agreement with AbbVie for its blood cancer drug candidate last week. AbbVie will also pay as much as $1.23 billion as various milestones are completed, as well as tiered, double-digit royalties on net sales. ISB 2001, the investigational drug to treat multiple myeloma, is in phase-1 clinical trials and has shown promising data. In a trial with 35 patients who had exhausted all existing lines of therapy unsuccessfully, 79% showed a clinical response to it, and 30% were cancer-free. 'I hope this acts as a catalyst to expanding the innovation landscape in India…we've demonstrated that you can do it," said Saldanha. Last bet ISB 2001, developed on IGI's proprietary BEAT platform, was the firm's last bet. 'There was no plan B," said Saldanha. 'This was pretty much the end of the road. At this point, the technology had to demonstrate that it worked…or we don't know what we would have done as the next thing." The drug had been in discovery over the last five years, while the company had been working on the BEAT platform for about a decade. There were three other assets that the company stopped developing. ISB 2001 has received both the US FDA Orphan Drug and Fast Track designations, highlighting its Orphan Drug designation is given to drugs treating rare diseases, while a fast track designation intends to expedite the development and review of drugs for treating serious conditions and fill unmet medical needs. Following the licensing agreement, AbbVie will take over further development for phase-2 and phase-3 trials before it can file for regulatory approval. The process would typically take four to five years. The market size for multiple myeloma is estimated to grow to $50 billion by 2030. Should the drug hit the markets in 2030, taking into account the tiered double-digit royalties, Glenmark stands to earn an additional $2.02 billion in royalties until 2041, according to research by brokerage Nuvama. The deal validates several aspects of Glenmark, including the strength of IGI's BEAT platform, the potential for ISB 2001 to treat relapsed/refractory multiple myeloma, and its commercial viability following successful clinical trials, said an 11 July note by Motilal Oswal analysts. 'Moreover, AbbVie has established itself as a diversified biopharma leader, combining scientific innovation with strong commercial execution. In oncology, the company has built a robust presence anchored by two cornerstone therapies: Imbruvica, a BTK inhibitor, and Venclexta, a BCL-2 inhibitor. These medicines have transformed the treatment landscape for chronic lymphocytic leukemia and other B-cell malignancies, generating multi-billion-dollar revenues and reinforcing AbbVie's reputation as a pioneer in hematologic cancer," the note added. Huge sacrifices, trade-offs Saldanha has bet on innovation since he took the reins of the company in the late 90s. A few years after Glenmark was listed in 2000, it established its first R&D centre for novel biologics research in Switzerland. Over the years, the company did a number of licensing deals with novel assets. In 2019, it spun off its R&D entity under a new company, Ichnos Sciences, which built on its proprietary BEAT bispecific platform. The two announced the creation of Ichnos Glenmark Innovation (IGI) in 2024. The company's focus on innovation created a lot of frustration for investors and stakeholders, Saldanha said. '[We were] bordering on being called eccentric," he said. The company also had to sell its stake in its active pharmaceutical ingredient (API) division, Glenmark Life Sciences, to pare its debt in 2023, which was approximately ₹4,500-4,600 crore. Glenmark sold 75% stake in the unit to industrial conglomerate Nirma for ₹5,650 crore. The company has made 'huge sacrifices, huge trade-offs," said Saldanha. With the GLS sale, the company had a choice to decide 'which end of the value chain we play", said Saldanha. 'Whether we play on this API stable end of the value chain, and generate revenues like that, or we play on the high end of the value chain, which is innovation." But innovation is not a cost game, he said. 'It's all about being able to understand where the therapy is going and how to come up with solutions." What's next for Glenmark? IGI spends about $70 million annually on new drug research. With the upfront payment it receives, it will be self-funded for the next three to four years, said Saldanha. The company will also look at rewarding shareholders with dividends. Apart from that, there are no immediate investment plans, said Saldanha. 'At least for the next year or two, we won't do anything. We'll just continue regrouping and trying to figure out strategically where we can further add value," he said. The deal is a big event for the company, which 'basically resets the whole agenda for the company", he said. 'We have to really reset and rethink how we want to see the company over the next five to ten years." ISB 2001's early success has validated the BEAT platform. 'We think we've now got it right with the technology…the idea is how can we exploit that technology much more effectively to add more products and do more," said Saldanha. The unit has another asset called ISB 2301, which is in late pre-clinical development and will go to the clinic next year. This drug will target solid tumours, said Saldanha. IGI also has a couple of other early-stage programs. '...over the next three, four years, we will exploit the technology as effectively as possible."
